Over the last 7 days, the market has dropped 1.7%, but it is up 17% over the past year with earnings expected to grow by 15% per annum. In this dynamic environment, identifying stocks with strong fundamentals can be crucial for investors looking to capitalize on hidden opportunities.
Name | Debt To Equity | Revenue Growth | Earnings Growth | Health Rating |
---|---|---|---|---|
River Financial | 131.04% | 17.59% | 20.70% | ★★★★★★ |
Morris State Bancshares | 14.93% | 0.44% | 7.74% | ★★★★★★ |
Omega Flex | NA | 2.13% | 4.77% | ★★★★★★ |
First Northern Community Bancorp | NA | 6.68% | 9.08% | ★★★★★★ |
Teekay | NA | -8.88% | 49.65% | ★★★★★★ |
Mission Bancorp | 25.37% | 16.23% | 20.16% | ★★★★★★ |
FirstSun Capital Bancorp | 27.36% | 10.54% | 30.73% | ★★★★★★ |
Gravity | NA | 15.31% | 24.42% | ★★★★★★ |
CSP | 2.17% | -5.57% | 73.73% | ★★★★★☆ |
FRMO | 0.19% | 6.49% | 15.82% | ★★★★☆☆ |
Let's dive into some prime choices out of from the screener.
Simply Wall St Value Rating: ★★★★★★
Overview: Ligand Pharmaceuticals Incorporated is a biopharmaceutical company focused on developing and licensing biopharmaceutical assets globally, with a market cap of $1.92 billion.
Operations: Ligand Pharmaceuticals generates revenue primarily from the development and licensing of biopharmaceutical assets, amounting to $118.31 million. The company has a market cap of approximately $1.92 billion.
Ligand Pharmaceuticals, a small-cap biotech firm, has seen earnings grow by 87.7% in the past year, outpacing the industry’s 19.9%. The company is debt-free now compared to five years ago when its debt-to-equity ratio was 59.6%. Despite significant insider selling recently, Ligand trades at 50.6% below its estimated fair value and forecasts a revenue growth of 19.8% annually. However, earnings are expected to decline by an average of 23.5% per year over the next three years.
Evaluate Ligand Pharmaceuticals' historical performance by accessing our past performance report.
Simply Wall St Value Rating: ★★★★☆☆
Overview: Meta Data Limited, with a market cap of $374.09 million, operates a K-12 after-school education platform specializing in young children's mathematics training and FasTrack English services in China and internationally.
Operations: Meta Data Limited generates revenue primarily from its educational services, specifically in education and training, amounting to $32.43 million. The company has a market cap of $374.09 million.
Meta Data, a small-cap company, recently executed a 1:5 stock split on July 29, 2024. Despite becoming profitable this year and having high-quality earnings, the company faces significant challenges. A winding-up petition was filed against it in April due to its inability to repay debts from a $139 million term facility drawn in March 2019. The debt-to-equity ratio surged from 41.1% to over 2151% in five years, indicating financial stress despite well-covered interest payments (4.4x EBIT).
Gain insights into Meta Data's past trends and performance with our Past report.
Simply Wall St Value Rating: ★★★★★☆
Overview: Worthington Steel, Inc. operates as a steel processor in North America with a market cap of $1.96 billion.
Operations: Worthington Steel generates revenue primarily from its Metal Processors and Fabrication segment, amounting to $3.43 billion.
Worthington Steel has shown impressive earnings growth of 77.7% over the past year, significantly outpacing the Metals and Mining industry's -26.6%. For fiscal 2024, sales reached US$3.43 billion with net income at US$154.7 million, up from US$87.1 million in 2023. The company’s net debt to equity ratio stands at a satisfactory 9.6%, and its interest payments are well covered by EBIT (35.9x). Worthington also trades at a notable discount of 27.4% below estimated fair value.
Assess Worthington Steel's past performance with our detailed historical performance reports.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
English